A phase II study of gefitinib in patients with metastatic melanoma

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 357-363

  Patel, Sapna P ^a   Kim, Kevin B ^a   Papadopoulos, Nicholas E ^a   Hwu, Wen Jen ^a   Hwu, Patrick ^a   Prieto, Victor G ^a   Bar Eli, Menashe ^a   Zigler, Maya ^a   Dobroff, Andrey ^a   Bronstein, Yulia ^a   Bassett, Roland L ^a   Vardeleon, Anna G ^a   Bedikian, Agop Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

epidermal growth factor receptor; gefitinib; metastatic melanoma; phase II

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GEFITINIB; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; P21 ACTIVATED KINASE 1; PROTEIN KINASE B; PROTEIN KINASE P60; VASCULOTROPIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER FATIGUE; CANCER STAGING; CANCER SURVIVAL; CHOROID MELANOMA; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; METASTATIC MELANOMA; NAUSEA AND VOMITING; NEUTROPENIA; NONCHOROIDAL MELANOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; SRC HOMOLOGY DOMAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHOROID NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TEXAS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960719395     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283471073     Document Type: Article

References (33)

1. De Wit PE, Moretti S, Koenders PG, Weterman MA, van Muijen GN, Gianotti B, Ruiter DJ. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992; 99:168-173.
2. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46:4726-4731. (Pubitemid 16000351)
3. Gordon-Thomson C, Mason RS, Moore GP. Regulation of epidermal growth factor receptor expression in human melanocytes. Exp Dermatol 2001; 10:321-328. (Pubitemid 32916281)
4. Slominski A, Ross J, Mihm MC. Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Br Med Bull 1995; 51:548-569.
5. Ohtake Y, Chen J, Gamou S, Takayanagi A, Mashima Y, Oguchi Y, Shimizu N. Ex-vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene. Jpn J Cancer Res 1999; 90:460-468. (Pubitemid 29213553)
6. Huang TS, Rauth S, Das Gupta TK. Overexpression of EGF receptor is associated with spontaneous metastases of a human melanoma cell line in nude mice. Anticancer Res 1996; 16:3557-3563. (Pubitemid 27085012)
7. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359:397-401. (Pubitemid 34158948)
8. Ma D, Niederkorn JY. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci 1998; 39:1067-1075. (Pubitemid 28247340)
9. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappa B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99:538-548. (Pubitemid 34461606)
10. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-265. (Pubitemid 29085177)
11. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754. (Pubitemid 35204731)
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
13. Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 1992; 11:853-862.
14. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-1818.
15. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
16. Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, Di Leone LP, Schwartsmann G. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 2004; 14:527-531. (Pubitemid 40221145)
17. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14:2367-2376. (Pubitemid 47174913)
18. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95:581-586. (Pubitemid 44325897)
19. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California cancer consortium. Cancer 2005; 104:1045-1048. (Pubitemid 41170233)
20. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954. (Pubitemid 34716871)
21. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147. (Pubitemid 41653105)
22. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126:154-160. (Pubitemid 43336107)
23. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006; 12 (7 Pt 2): 2301s-2307s.
24. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16:267-273. (Pubitemid 44090170)
25. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007; 28:578-588. (Pubitemid 46744288)
26. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599-602.
27. Yeh AH, Bohula EA, Macaulay VM. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006; 25:6574-6581. (Pubitemid 44646185)
28. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005; 92:2097-2101. (Pubitemid 40966242)
29. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001; 61:7318-7324. (Pubitemid 32946531)
30. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C. IGF1 promotes resistance to apoptosis inmelanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 2008; 128:1499-1505. (Pubitemid 351693181)
31. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. New Eng J Med 2006; 354:526-528.
32. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008; 18:29-35. (Pubitemid 351628053)
33. Flaherty K, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Eng J Med 2010; 363:808-819.